Circulating DNA in EGFR-mutated lung cancer

Aditi P. Singh, Shenduo Li, Haiying Cheng

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Circulating tumor DNA (ctDNA) consists of short double stranded DNA fragments that are released by tumors including non-small cell lung cancer (NSCLC). With the identification of driver mutations in the epidermal growth factor receptor (EGFR) gene and development of targeted tyrosine kinase inhibitors (TKIs), the clinical outcome of NSCLC patients in this subgroup has improved tremendously. The gold standard to assess EGFR mutation is through tissue biopsy, which can be limited by difficulty in accessing the tumor, inability of patients to tolerate invasive procedures, insufficient sample for molecular testing and inability to capture intratumoral heterogeneity. The great need for rapid and accurate identification of activating EGFR mutations in NSCLC patients paves the road for ctDNA technology. Studies have demonstrated ctDNA to be a reliable complement to tumor genotyping. Platforms like digital polymerase chain reaction (PCR) and next-generation sequencing based analyses have made it possible to identify EGFR mutations in plasma with high sensitivity and specificity. This article will provide an overview on ctDNA in the context of EGFR mutated NSCLC, especially its emerging applications in diagnosis, disease surveillance, treatment monitoring and detection of resistance mechanisms.

Original languageEnglish (US)
Article number379
JournalAnnals of Translational Medicine
Volume5
Issue number18
DOIs
StatePublished - Sep 1 2017

Fingerprint

Epidermal Growth Factor Receptor
Lung Neoplasms
DNA
Non-Small Cell Lung Carcinoma
Neoplasms
Mutation
erbB-1 Genes
Protein-Tyrosine Kinases
Technology
Biopsy
Sensitivity and Specificity
Polymerase Chain Reaction

Keywords

  • Circulating tumor DNA (ctDNA)
  • Epidermal growth factor receptor mutation (EGFR mutation)
  • Liquid biopsy
  • Non-small cell lung cancer (NSCLC)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Circulating DNA in EGFR-mutated lung cancer. / Singh, Aditi P.; Li, Shenduo; Cheng, Haiying.

In: Annals of Translational Medicine, Vol. 5, No. 18, 379, 01.09.2017.

Research output: Contribution to journalArticle

Singh, Aditi P. ; Li, Shenduo ; Cheng, Haiying. / Circulating DNA in EGFR-mutated lung cancer. In: Annals of Translational Medicine. 2017 ; Vol. 5, No. 18.
@article{3c0ae70bacd5438cadd581fd640b7c8a,
title = "Circulating DNA in EGFR-mutated lung cancer",
abstract = "Circulating tumor DNA (ctDNA) consists of short double stranded DNA fragments that are released by tumors including non-small cell lung cancer (NSCLC). With the identification of driver mutations in the epidermal growth factor receptor (EGFR) gene and development of targeted tyrosine kinase inhibitors (TKIs), the clinical outcome of NSCLC patients in this subgroup has improved tremendously. The gold standard to assess EGFR mutation is through tissue biopsy, which can be limited by difficulty in accessing the tumor, inability of patients to tolerate invasive procedures, insufficient sample for molecular testing and inability to capture intratumoral heterogeneity. The great need for rapid and accurate identification of activating EGFR mutations in NSCLC patients paves the road for ctDNA technology. Studies have demonstrated ctDNA to be a reliable complement to tumor genotyping. Platforms like digital polymerase chain reaction (PCR) and next-generation sequencing based analyses have made it possible to identify EGFR mutations in plasma with high sensitivity and specificity. This article will provide an overview on ctDNA in the context of EGFR mutated NSCLC, especially its emerging applications in diagnosis, disease surveillance, treatment monitoring and detection of resistance mechanisms.",
keywords = "Circulating tumor DNA (ctDNA), Epidermal growth factor receptor mutation (EGFR mutation), Liquid biopsy, Non-small cell lung cancer (NSCLC)",
author = "Singh, {Aditi P.} and Shenduo Li and Haiying Cheng",
year = "2017",
month = "9",
day = "1",
doi = "10.21037/atm.2017.07.10",
language = "English (US)",
volume = "5",
journal = "Annals of Translational Medicine",
issn = "2305-5839",
publisher = "AME Publishing Company",
number = "18",

}

TY - JOUR

T1 - Circulating DNA in EGFR-mutated lung cancer

AU - Singh, Aditi P.

AU - Li, Shenduo

AU - Cheng, Haiying

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Circulating tumor DNA (ctDNA) consists of short double stranded DNA fragments that are released by tumors including non-small cell lung cancer (NSCLC). With the identification of driver mutations in the epidermal growth factor receptor (EGFR) gene and development of targeted tyrosine kinase inhibitors (TKIs), the clinical outcome of NSCLC patients in this subgroup has improved tremendously. The gold standard to assess EGFR mutation is through tissue biopsy, which can be limited by difficulty in accessing the tumor, inability of patients to tolerate invasive procedures, insufficient sample for molecular testing and inability to capture intratumoral heterogeneity. The great need for rapid and accurate identification of activating EGFR mutations in NSCLC patients paves the road for ctDNA technology. Studies have demonstrated ctDNA to be a reliable complement to tumor genotyping. Platforms like digital polymerase chain reaction (PCR) and next-generation sequencing based analyses have made it possible to identify EGFR mutations in plasma with high sensitivity and specificity. This article will provide an overview on ctDNA in the context of EGFR mutated NSCLC, especially its emerging applications in diagnosis, disease surveillance, treatment monitoring and detection of resistance mechanisms.

AB - Circulating tumor DNA (ctDNA) consists of short double stranded DNA fragments that are released by tumors including non-small cell lung cancer (NSCLC). With the identification of driver mutations in the epidermal growth factor receptor (EGFR) gene and development of targeted tyrosine kinase inhibitors (TKIs), the clinical outcome of NSCLC patients in this subgroup has improved tremendously. The gold standard to assess EGFR mutation is through tissue biopsy, which can be limited by difficulty in accessing the tumor, inability of patients to tolerate invasive procedures, insufficient sample for molecular testing and inability to capture intratumoral heterogeneity. The great need for rapid and accurate identification of activating EGFR mutations in NSCLC patients paves the road for ctDNA technology. Studies have demonstrated ctDNA to be a reliable complement to tumor genotyping. Platforms like digital polymerase chain reaction (PCR) and next-generation sequencing based analyses have made it possible to identify EGFR mutations in plasma with high sensitivity and specificity. This article will provide an overview on ctDNA in the context of EGFR mutated NSCLC, especially its emerging applications in diagnosis, disease surveillance, treatment monitoring and detection of resistance mechanisms.

KW - Circulating tumor DNA (ctDNA)

KW - Epidermal growth factor receptor mutation (EGFR mutation)

KW - Liquid biopsy

KW - Non-small cell lung cancer (NSCLC)

UR - http://www.scopus.com/inward/record.url?scp=85029696158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029696158&partnerID=8YFLogxK

U2 - 10.21037/atm.2017.07.10

DO - 10.21037/atm.2017.07.10

M3 - Article

VL - 5

JO - Annals of Translational Medicine

JF - Annals of Translational Medicine

SN - 2305-5839

IS - 18

M1 - 379

ER -